MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • MDS Virtual Congress 2020

    A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes

    A. Thach, J. Sutphin, J. Coulter, C. Mansfield (Marlborough, MA, USA)

    Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…
  • MDS Virtual Congress 2020

    Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations

    A. Lees, J. Ferreira, W. Poewe, H. Gama, D. Magalhães, J.F Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate the potential added benefit of opicapone (OPC), compared with placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients…
  • MDS Virtual Congress 2020

    Identification and characterization of anti-prionic compounds that disassemble αSyn prions as a novel therapeutic approach for synucleinopathies

    D. Willbold, M. Sevenich, W. Hoyer, J. Mohrlüder, A. Willuweit (Jülich, Germany)

    Objective: Stabilization of monomeric α-synuclein protein (αSyn) by transient and high-affinity binding ligands is a novel and highly innovative anti-prionic treatment strategy for synucleinopathies .…
  • MDS Virtual Congress 2020

    Identification and characterization of anti-prionic compounds that disassemble Tau prions as a novel therapeutic approach for tauopathies

    D. Willbold, T. Altendorf, W. Hoyer, J. Mohrlüder (Jülich, Germany)

    Objective: Stabilization of monomeric Tau protein by transient and high-affinity binding ligands is a novel and highly innovative anti-prionic treatment strategy for tauopathies. Background: Tauopathies…
  • MDS Virtual Congress 2020

    Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes

    A. Thach, N. Kirson, M. Zichlin, I. Dieye, E. Pappert, G. Williams (Marlborough, MA, USA)

    Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…
  • MDS Virtual Congress 2020

    Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis

    A. Lees, H. Reichmann, J.F Rocha, D. Magalhães, P. Soares-da-Silva (London, United Kingdom)

    Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…
  • MDS Virtual Congress 2020

    Refractory tremor: is perampanel a potentially useful therapy?

    Á. Beltrán, F. Rodríguez, J.L Chico, P. Parra, I. Pareés, J.C Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)

    Objective: To describe our series of patients with refractory tremor eventually treated with perampanel and to analyse its clinical outcomes. Background: Up to 40% of…
  • 2019 International Congress

    Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality

    CA. Artusi, R. Balestrino, G. Imbalzano, S. Bortolani, S. Tuttobene, E. Montanaro, M. Zibetti, L. Lopiano (Torino, Italy)

    Objective: We sought to analyze the mortality and the causes of death of 105 patients with Parkinson disease (PD) treated with levodopa-carbidopa intestinal gel (LCIG)…
  • 2019 International Congress

    The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program

    R. Hauser, D. Kremens, D. Chernick, R. Patni, J. Hubble (Tampa, FL, USA)

    Objective: To assess the impact of Gocovri® (amantadine) extended release capsules on motor aspects of experiences of daily living in PD patients. Background: Gocovri is…
  • 2019 International Congress

    The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program

    R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)

    Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Life expectancy with and without Parkinson’s disease in the general population
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • #28953 (not found)
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley